Sindrome da anticorpi antifosfolipidi e tromboembolismo venoso: Il ruolo della trombofilia congenita

Translated title of the contribution: Antiphospholipid syndrome and venous thromboembolism: The role of inherited thrombophilia

Daniela Poli, Gian Franco Gensini

Research output: Contribution to journalArticle

Abstract

The antiphospholipid syndrome is associated with complications of pregnancy or venous or arterial thrombosis in the presence of antiphospholipid antibodies. Venous thromboembolism is the most common clinical feature. Pathogenetic mechanisms underlying the syndrome are not completely understood and several hypotheses have been raised. Secondary prophylaxis after venous thromboembolism episodes requires oral anticoagulants (prothrombin time-international normalized ratio 2-3) for 6 to 12 months. More intensive anticoagulant regimens are indicated in case of recurrence. A longer or life-long course of treatment is indicated in patients with recurrent or life-threatening events or in the presence of high titers of antiphospholipid antibodies. Among risk factors for venous thromboembolism, inherited thrombophilia is recently described, such as defects of the physiological coagulation inhibitors, genetic mutations of factor V and factor II of the coagulation cascade and hyperhomocysteinemia. High levels of factor VIII, factor IX and Iipoprotein(a) have recently been proposed as new risk factors for venous thromboembolism. The coexistence of inherited thrombophilia seems to enhance the thrombogenic risk, in particular in the venous vascular bed. The new insights into the diagnosis of inherited thrombophilia could allow a better evaluation of the thrombotic risk, leading to tailor the prophylactic strategy.

Original languageItalian
Pages (from-to)218-223
Number of pages6
JournalAnnali Italiani di Medicina Interna
Volume20
Issue number4
Publication statusPublished - Oct 2005

Fingerprint

Antiphospholipid Syndrome
Thrombophilia
Venous Thromboembolism
Antiphospholipid Antibodies
Anticoagulants
Hyperhomocysteinemia
Factor IX
International Normalized Ratio
Factor V
Pregnancy Complications
Prothrombin Time
Factor VIII
Prothrombin
Blood Vessels
Thrombosis
Recurrence
Mutation
Therapeutics

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Sindrome da anticorpi antifosfolipidi e tromboembolismo venoso : Il ruolo della trombofilia congenita. / Poli, Daniela; Gensini, Gian Franco.

In: Annali Italiani di Medicina Interna, Vol. 20, No. 4, 10.2005, p. 218-223.

Research output: Contribution to journalArticle

@article{d3bf0f639788461ba76ba4f6c68125a7,
title = "Sindrome da anticorpi antifosfolipidi e tromboembolismo venoso: Il ruolo della trombofilia congenita",
abstract = "The antiphospholipid syndrome is associated with complications of pregnancy or venous or arterial thrombosis in the presence of antiphospholipid antibodies. Venous thromboembolism is the most common clinical feature. Pathogenetic mechanisms underlying the syndrome are not completely understood and several hypotheses have been raised. Secondary prophylaxis after venous thromboembolism episodes requires oral anticoagulants (prothrombin time-international normalized ratio 2-3) for 6 to 12 months. More intensive anticoagulant regimens are indicated in case of recurrence. A longer or life-long course of treatment is indicated in patients with recurrent or life-threatening events or in the presence of high titers of antiphospholipid antibodies. Among risk factors for venous thromboembolism, inherited thrombophilia is recently described, such as defects of the physiological coagulation inhibitors, genetic mutations of factor V and factor II of the coagulation cascade and hyperhomocysteinemia. High levels of factor VIII, factor IX and Iipoprotein(a) have recently been proposed as new risk factors for venous thromboembolism. The coexistence of inherited thrombophilia seems to enhance the thrombogenic risk, in particular in the venous vascular bed. The new insights into the diagnosis of inherited thrombophilia could allow a better evaluation of the thrombotic risk, leading to tailor the prophylactic strategy.",
keywords = "Antiphospholipid syndrome, Inherited thrombophilia, Venous thromboembolism",
author = "Daniela Poli and Gensini, {Gian Franco}",
year = "2005",
month = "10",
language = "Italian",
volume = "20",
pages = "218--223",
journal = "Annali Italiani di Medicina Interna",
issn = "0393-9340",
publisher = "CEPI s.r.l.",
number = "4",

}

TY - JOUR

T1 - Sindrome da anticorpi antifosfolipidi e tromboembolismo venoso

T2 - Il ruolo della trombofilia congenita

AU - Poli, Daniela

AU - Gensini, Gian Franco

PY - 2005/10

Y1 - 2005/10

N2 - The antiphospholipid syndrome is associated with complications of pregnancy or venous or arterial thrombosis in the presence of antiphospholipid antibodies. Venous thromboembolism is the most common clinical feature. Pathogenetic mechanisms underlying the syndrome are not completely understood and several hypotheses have been raised. Secondary prophylaxis after venous thromboembolism episodes requires oral anticoagulants (prothrombin time-international normalized ratio 2-3) for 6 to 12 months. More intensive anticoagulant regimens are indicated in case of recurrence. A longer or life-long course of treatment is indicated in patients with recurrent or life-threatening events or in the presence of high titers of antiphospholipid antibodies. Among risk factors for venous thromboembolism, inherited thrombophilia is recently described, such as defects of the physiological coagulation inhibitors, genetic mutations of factor V and factor II of the coagulation cascade and hyperhomocysteinemia. High levels of factor VIII, factor IX and Iipoprotein(a) have recently been proposed as new risk factors for venous thromboembolism. The coexistence of inherited thrombophilia seems to enhance the thrombogenic risk, in particular in the venous vascular bed. The new insights into the diagnosis of inherited thrombophilia could allow a better evaluation of the thrombotic risk, leading to tailor the prophylactic strategy.

AB - The antiphospholipid syndrome is associated with complications of pregnancy or venous or arterial thrombosis in the presence of antiphospholipid antibodies. Venous thromboembolism is the most common clinical feature. Pathogenetic mechanisms underlying the syndrome are not completely understood and several hypotheses have been raised. Secondary prophylaxis after venous thromboembolism episodes requires oral anticoagulants (prothrombin time-international normalized ratio 2-3) for 6 to 12 months. More intensive anticoagulant regimens are indicated in case of recurrence. A longer or life-long course of treatment is indicated in patients with recurrent or life-threatening events or in the presence of high titers of antiphospholipid antibodies. Among risk factors for venous thromboembolism, inherited thrombophilia is recently described, such as defects of the physiological coagulation inhibitors, genetic mutations of factor V and factor II of the coagulation cascade and hyperhomocysteinemia. High levels of factor VIII, factor IX and Iipoprotein(a) have recently been proposed as new risk factors for venous thromboembolism. The coexistence of inherited thrombophilia seems to enhance the thrombogenic risk, in particular in the venous vascular bed. The new insights into the diagnosis of inherited thrombophilia could allow a better evaluation of the thrombotic risk, leading to tailor the prophylactic strategy.

KW - Antiphospholipid syndrome

KW - Inherited thrombophilia

KW - Venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=33745525297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745525297&partnerID=8YFLogxK

M3 - Articolo

C2 - 16610253

AN - SCOPUS:33745525297

VL - 20

SP - 218

EP - 223

JO - Annali Italiani di Medicina Interna

JF - Annali Italiani di Medicina Interna

SN - 0393-9340

IS - 4

ER -